Australia markets close in 5 hours 59 minutes

Crinetics Pharmaceuticals, Inc. (CRNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
45.05+1.23 (+2.81%)
At close: 04:00PM EDT
45.05 0.00 (0.00%)
After hours: 04:20PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 3.45B
Enterprise value 2.94B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)633.82
Price/book (mrq)6.40
Enterprise value/revenue 733.16
Enterprise value/EBITDA -13.28

Trading information

Stock price history

Beta (5Y monthly) 0.62
52-week change 3103.15%
S&P500 52-week change 323.10%
52-week high 349.58
52-week low 315.76
50-day moving average 343.06
200-day moving average 332.15

Share statistics

Avg vol (3-month) 3804.88k
Avg vol (10-day) 3564.03k
Shares outstanding 578.74M
Implied shares outstanding 679.83M
Float 864.8M
% held by insiders 11.92%
% held by institutions 196.10%
Shares short (15 Apr 2024) 45.22M
Short ratio (15 Apr 2024) 44.77
Short % of float (15 Apr 2024) 47.35%
Short % of shares outstanding (15 Apr 2024) 46.70%
Shares short (prior month 15 Mar 2024) 45.01M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-5,547.17%

Management effectiveness

Return on assets (ttm)-28.18%
Return on equity (ttm)-50.16%

Income statement

Revenue (ttm)4.01M
Revenue per share (ttm)0.07
Quarterly revenue growth (yoy)-100.00%
Gross profit (ttm)N/A
EBITDA -221.51M
Net income avi to common (ttm)-214.53M
Diluted EPS (ttm)-3.69
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)558.56M
Total cash per share (mrq)8.03
Total debt (mrq)51.73M
Total debt/equity (mrq)9.59%
Current ratio (mrq)13.07
Book value per share (mrq)7.91

Cash flow statement

Operating cash flow (ttm)-166.31M
Levered free cash flow (ttm)-93.53M